Royal UNIBREW A/S
COMPANY ANNOUNCEMENT NO 11/2021 – 8 MARCH 2021
On 3 March 2021, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 9/2021 of 3 March 2021. The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (the Market Abuse Regulation - MAR) and the resulting delegated legislation. The share buy-back program is expected to be realized in the period from 4 March 2021 to 30 June 2021. The total share buy-back in the period will not exceed a market price of DKK 250 million.
The following transactions have been made under the program:
Number of Shares | Average purchase price | Transaction value, DKK | |
Accumulated, last announcement | 0 | - | - |
4 March 2021 | 3,450 | 622.53 | 2,147,724.02 |
5 March 2021 | 1,793 | 643.80 | 1,154,325.15 |
Accumulated under the program | 5,243 | 629.80 | 3,302,049.17 |
With the transactions stated above Royal Unibrew owns a total of 772,683 shares, corresponding to 1.6% of the share capital. The total amount of shares in the company is 49,350,000, including treasury shares.
For further information on this Announcement:
CFO Lars Vestergaard, tel (+45) 30 93 18 08
www.royalunibrew.com
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Bitget Limited17.9.2025 05:42:07 CEST | Press release
Bitget Turns 7, Coining the ‘Universal Exchange’ as the Next Generation of Exchanges
CGTN17.9.2025 03:06:57 CEST | Pressemeddelelse
CGTN: Film om Japans berygtede biologiske krigsførelsesenhed fra Anden Verdenskrig får premiere den 18. september
Teva Pharmaceutical Industries Ltd16.9.2025 22:30:00 CEST | Press release
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
Society of Actuaries16.9.2025 20:46:16 CEST | Press release
Society of Actuaries Announces Planned CEO Succession in 2026
Lehman Brothers UK Capital Funding LP16.9.2025 17:53:36 CEST | Press release
Lehman Brothers UK Capital Funding LP: Notice of Proposed Interim Payment
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom